Immediate clinical assessment of medical intervention in schizophrenic patients admitted to an acute-care psychiatric unit: A retrospective, naturalistic and multicenter study

References

• Bromet EJ, Fenning S. Epidemiology and natural history of schizophrenia. Biol Psychiatry 1999;46:871–81.
   PubMed Web of Science ®Google Scholar
• McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004;2:13.
   PubMed Web of Science ®Google Scholar
• Kelly BD, O'Callaghan E, Waddington JL, Feeney L, Browne S, Scully PJ, . Schizophrenia and the city: A review of literature and prospective study of psychosis and urbanicity in Ireland. Schizophr Res 2010;116:75–89.
   PubMed Web of Science ®Google Scholar
• McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67–76.
   PubMed Web of Science ®Google Scholar
• Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician 2007;75:1821–9.
   PubMed Web of Science ®Google Scholar
• Müller N. Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry 2004;37(Suppl 2):S141–7.
   Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, . Long-term [7] outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009;24(5):287–96.
   PubMedGoogle Scholar
• Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209–22.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, . The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010;10:2.
   PubMed Web of Science ®Google Scholar
• Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346–51.
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002;16:473–84.
   PubMed Web of Science ®Google Scholar
• Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305–12.
   PubMed Web of Science ®Google Scholar
• Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 2008;34: 173–80.
   PubMed Web of Science ®Google Scholar
• Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005;3:21.
   PubMed Web of Science ®Google Scholar
• Lenroot R, Bustillo JR, Lauriello J, Keith SJ. Integrated treatment of schizophrenia. Psychiatr Serv 2003;54:1499–507.
   PubMed Web of Science ®Google Scholar
• Bustillo J, Lauriello J, Horan W, Keith S. The psychosocial treatment of schizophrenia: an update. Am J Psychiatr 2001;158:163–75.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th. (DSM-IV). American Psychiatric Association, Washington; 1994.
   Google Scholar
• García Cabeza I, Hormaechea Beldarraín JA, Arango López C, Sanz Amador, M, González de Chávez MT. El cuestionario de Actitud hacia la Medicación (Drug Attitude Inventory: DAI-30) en población española. Arch Neurobiol 2001;64:261–72.
   Google Scholar
• Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008;8:32.
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Schuster T, Peters S, Kissling W. Partial compliance with antipsychotic medication is common in patients with schizophrenia. Aust NZ J Psychiatry 2008;42:382–8.
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, . Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692–9.
   PubMed Web of Science ®Google Scholar
• Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996;47:853–8.
   PubMed Web of Science ®Google Scholar
• Dolder CR, Lacro JP, Leckband S, Jeste DV. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 2003; 23:389–99.
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Rosch DS, Sivec HJ, Sultana D, Smith DA, Alamir S, . Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv 2002;53:1319–21.
   PubMed Web of Science ®Google Scholar
• Awad GA. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993;19:609–18.
   PubMed Web of Science ®Google Scholar
• Levine S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry 2010;68:86–92.
   PubMed Web of Science ®Google Scholar